Binglan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Binglan Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chenglong Zhang
College of Basic Medical Sciences, Harbin Medical University, Harbin, China
1 shared publication Fuping Zhu
Department of General Surgery, the Ninth People‘s Hospital of Chongqing, Chongqing, China
1 shared publication- Jing Zhu
Department of Oncology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication Pan Li
Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationZhou Rui
Department of Oncology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 28 December 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33 (4) , 563-570
Diagnostic Value of Qualitative and Quantitative Endoscopic Ultrasound Elastography for the Evaluation of Lymph Nodes: A Meta-analysis
Background and Aims: The differential diagnosis of benign and malignant deep lymph nodes (LNs) has been a significant challenge up until now. Endoscopic ultrasound (EUS) elastography is a real-time imaging technique evaluated in several studies with diverse results. A meta-analysis was performed to assess the performance of EUS elastography for the differentiation of benign and malignant deep LNs. Methods: All the eligible studies were searched by PubMed, Medline, Embase, and the Cochrane Library. A meta-analysis was performed to obtain pooled sensitivity, specificity, positive and negative likelihood ratio (LR). The diagnostic odds ratio (DOR) and area under the curve (AUC) were used to examine the accuracy of qualitative and quantitative EUS elastography. Results: A total of eleven studies including 599 patients and 943 LNs were analyzed. In studies using the qualitative color pattern as the diagnostic standard, the pooled sensitivity, specificity, positive and negative LR were 0.82 [95% confidence interval (CI): 0.77-0.86)], 0.92 (95%CI: 0.89-0.94), 7.83 (95%CI: 3.58-17.09) and 0.22 (95%CI: 0.14-0.34), respectively. In studies using the quantitative value as the diagnostic standard, the pooled sensitivity, specificity, positive and negative LR were 0.80 (95%CI: 0.74-0.86) and 0.87 (95%CI: 0.82-0.92), 5.63 (95%CI: 3.46-9.17) and 0.23 (95%CI: 0.12-0.44), respectively. The summary DOR and the AUC were 48.73 (95%CI: 21.83-108.80) and 0.933 (Q*=0.869) for qualitative EUS elastography, 33.35 (95% CI: 12.81-86.87) and 0.923 (Q*=0.857) for quantitative EUS elastography. Conclusions: Our meta-analysis shows that both qualitative and quantitative EUS elastography have high accuracy in the detection of malignant deep LNs, which could be used as a valuable complementary method to EUS-FNA for the differentiation of deep LNs in the future.
- 28 December 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33 (4) , 563-570
Open AccessDiagnostic Value of Qualitative and Quantitative Endoscopic Ultrasound Elastography for the Evaluation of Lymph Nodes: A Meta-analysis
Background and Aims: The differential diagnosis of benign and malignant deep lymph nodes (LNs) has been a significant challenge up until now. Endoscopic ultrasound (EUS) elastography is a real-time imaging technique evaluated in several studies with diverse results. A meta-analysis was performed to assess the performance of EUS elastography for the differentiation of benign and malignant deep LNs. Methods: All the eligible studies were searched by PubMed, Medline, Embase, and the Cochrane Library. A meta-analysis was performed to obtain pooled sensitivity, specificity, positive and negative likelihood ratio (LR). The diagnostic odds ratio (DOR) and area under the curve (AUC) were used to examine the accuracy of qualitative and quantitative EUS elastography. Results: A total of eleven studies including 599 patients and 943 LNs were analyzed. In studies using the qualitative color pattern as the diagnostic standard, the pooled sensitivity, specificity, positive and negative LR were 0.82 [95% confidence interval (CI): 0.77-0.86)], 0.92 (95%CI: 0.89-0.94), 7.83 (95%CI: 3.58-17.09) and 0.22 (95%CI: 0.14-0.34), respectively. In studies using the quantitative value as the diagnostic standard, the pooled sensitivity, specificity, positive and negative LR were 0.80 (95%CI: 0.74-0.86) and 0.87 (95%CI: 0.82-0.92), 5.63 (95%CI: 3.46-9.17) and 0.23 (95%CI: 0.12-0.44), respectively. The summary DOR and the AUC were 48.73 (95%CI: 21.83-108.80) and 0.933 (Q*=0.869) for qualitative EUS elastography, 33.35 (95% CI: 12.81-86.87) and 0.923 (Q*=0.857) for quantitative EUS elastography. Conclusions: Our meta-analysis shows that both qualitative and quantitative EUS elastography have high accuracy in the detection of malignant deep LNs, which could be used as a valuable complementary method to EUS-FNA for the differentiation of deep LNs in the future.
- 5 July 2019
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (9) , 2313-2323
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
The optimal treatment in the third-line and later-line setting for metastatic colorectal cancer (mCRC) has not been established. As reported, regorafenib and fruquintinib have shown to be superior to placebo in mCRC. However, no direct clinical comparison of regorafenib and fruquintinib has been conducted; we performed a systematic review and network meta-analysis to compare the efficacy and safety of regorafenib and fruquintinib.
- 5 July 2019
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (9) , 2313-2323
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
The optimal treatment in the third-line and later-line setting for metastatic colorectal cancer (mCRC) has not been established. As reported, regorafenib and fruquintinib have shown to be superior to placebo in mCRC. However, no direct clinical comparison of regorafenib and fruquintinib has been conducted; we performed a systematic review and network meta-analysis to compare the efficacy and safety of regorafenib and fruquintinib.